Vernon G. Wong, MD, FACS, is the founder of Icon Bioscience, Inc. Dr. Wong is a pioneer in the field of drug delivery dating back to the early 1970’s. Dr. Wong was the first clinical director of the National Eye Institute and was a tenured Professor at Georgetown University Medical School. He has published over 100 scientific papers. He co-founded and was the core patent holder in Oculex Pharmaceuticals, which was acquired by Allergan Pharmaceuticals for $245 million in 2002.
President & Chief Executive Officer
David S. Tierney, M.D.
David S. Tierney, MD joined the Company as President & Chief Executive Officer in March 2014. Previously, Dr. Tierney served as President & COO of Oceana Therapeutics, Inc., a specialty therapeutic company he co-founded in mid-2008. Oceania quickly established a global commercial network and by December 2011 was acquired by Salix Pharmaceuticals. In 2000, David was appointed President & CEO of Hydro Med Sciences (HMS), a research firm with a promising drug delivery platform. Under his leadership, HMS emerged as Valera Pharmaceuticals, a fully integrated, commercial, specialty pharma company that successfully completed an initial public offering in 2005. Valera has since been merged into Endo Pharmaceuticals. Prior to Valera, Dr. Tierney was President of Biovail Technologies, a drug delivery division of Biovail Corporation – a predecessor to Valeant Pharmaceuticals International. Earlier in his career, he served as Senior VP, Drug Development at Roberts Pharmaceutical and in a variety of management positions at Elan Corporation.
A recipient of 2005 and 2011 Ernst & Young Entrepreneur Of The Year® Awards, David was named to the 2005, 2006 and 2011 PharmaVOICE lists of the 100 Most Inspiring People in the Life Sciences Industry. He was also featured in the 2010 inaugural Irish Life Science 50, an honor bestowed by the Irish Voice newspaper and Irish America magazine in conjunction with the Irish Government. David received his medical degree from the Royal College of Surgeons in Dublin, Ireland.
Vice President, Clinical Development
Wendy Yee Murahashi, MD joined IBI in October, 2011 and is responsible for all regulatory and clinical activities. She is an American Academy of Ophthalmology board-certified ophthalmologist with subspecialty training in retina and vitreous. She previously served as Clinical Instructor at the Portland VA Hospital/Casey Eye Institute. Prior to joining IBI, Dr. Murahashi was a Medical Director at Genentech/Roche with clinical trial responsibility involving the Lucentis® program.
Vice President, Finance & Administration
Mr. Hector Casab joined Icon Bioscience in January 2014 and is responsible for all finance and accounting activities. Prior to joining IBI, Mr. Casab was head of Financial Planning at Onyx Pharmaceuticals, supporting the company’s operational and financial growth of multiple product launches in oncology. He previously held roles in finance and operations at Genentech and Applied Biosystems. Mr. Casab earned his MBA from Santa Clara University.
Mr. David Williams has over 25 years of experience in cGMP large and small molecule manufacturing operations, process development/ scale-up, facility design and construction, state and local incentive development programs, and R&D. Prior to TS consulting, he was Senior Vice President of Operations for Chlorogen, Inc., in St. Louis, MO. He joined Chlorogen in June 2003 from CropTech Corporation in Blacksburg, Virginia, where he served as Chief Technology Officer and Sr. VP of Operations. Mr. Williams also served with Monsanto Company as Vice President of Operations for the Integrated Protein Technologies (IPT) business unit; Cephalon, Inc., as Director of Operations; founding partner and VP of Operations for Bio Science Contract Production Corporation (which became Cambrex Bio Science); and North American Vaccine as Director of Manufacturing for pediatric vaccines. Mr. Williams holds a M.S. degree in industrial Microbiology/Biochemistry, and completed PhD. requirements, all but dissertation, in Microbiology/Biochemistry from the University of Oklahoma.